ARQT — Arcutis Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787306 ·
Last close
$26.92
Market Cap
$3.38B
52W High
$31.77
52W Low
$16.71
ADV30
2,812,610
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 129,861,000 | 118,922,000 | 16,429,000 | 15,009,000 | 488,537,000 | 34,121,000 | 267,958,000 |
| Mar 2026 | 105,398,000 | 95,614,000 | -9,089,000 | -11,295,000 | 460,003,000 | 34,762,000 | 270,355,000 |
| Dec 2025 | 129,503,000 | 117,815,000 | 18,387,000 | 17,395,000 | 432,973,000 | 42,907,000 | 243,494,000 |
| Sep 2025 | 99,219,000 | 90,534,000 | 8,526,000 | 7,410,000 | 370,977,000 | 47,120,000 | 212,904,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$39,309,000
Investing CF
$-85,982,000
Financing CF
$8,255,000
CapEx
$-15,686,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.21
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,134,370,000
Inventory
$38,879,000
Receivables
$155,162,000
ST Investments
$204,431,000
EBIT TTM
$43,144,000
Pretax Income TTM
$29,298,000
Interest Exp TTM
$13,846,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$463,980,992
EBITDA
$36,503,000
Free Cash Flow
$21,685,376
Enterprise Value
$2,877,737,472
Total Cash
$238,552,000
Total Debt
$114,137,000
Shares Out
125,691,961
Trailing EPS
$0.22
Book Value
$1.76
ROE
15.9%
ROA
5.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 376,072,000 | -12,227,000 | -16,141,000 | 432,973,000 | 243,494,000 | 189,479,000 | -5,625,000 |
| Dec 2024 | 196,542,000 | -128,397,000 | -140,039,000 | 348,889,000 | 191,348,000 | 157,541,000 | -112,158,000 |
| Dec 2023 | 59,606,000 | -241,101,000 | -262,140,000 | 341,365,000 | 252,698,000 | 88,667,000 | -247,057,000 |
| Dec 2022 | 3,686,000 | -301,627,000 | -311,458,000 | 449,274,000 | 239,693,000 | 209,581,000 | -257,715,000 |
TTM Snapshot
Revenues TTM
$149,435,000
NetIncome TTM
$-219,071,000
OpCashFlow TTM
$0
Assets (Latest)
$432,973,000
Forward EPS
$1.30
Max Pain — expiry 2026-10-16
max pain strike: $27.50 · spot: $26.92 · call oi: 4,573 · put oi: 217
Expected Move to 2026-10-16:
±$3.88
(14.41%) —
implied range
$23.04 –
$30.80
· ATM straddle on $27.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.29B | $29.49 | — |
| ELVN | Enliven Therapeutics, Inc. | $3.28B | $44.75 | — |
| IDYA | IDEAYA Biosciences, Inc. | $3.54B | $36.69 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.56B | $20.68 | — |
| XENE | Xenon Pharmaceuticals Inc. | $3.58B | $36.94 | — |
News headlines (Yahoo Finance, 1h cache)
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
2026-09-17 14:38 · Yahoo
Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11%
2026-09-17 07:20 · Yahoo
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-04 20:00 · Yahoo
Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain?
2026-08-28 01:07 · Yahoo
Arcutis (ARQT) Q2 2026 Earnings Call Transcript
2026-08-12 21:28 · Yahoo
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
2026-08-06 12:50 · Yahoo
Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% and ...
2026-08-06 05:08 · Yahoo
AXT Inc. (AXTI) Climbs 16% on S&P 600 Addition
2026-09-21 20:00 · Yahoo
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
2026-08-27 08:27 · Yahoo
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
2026-08-24 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.